Document is current

Article History

Accepted: 16 December 2024

First Online: 17 January 2025

Declarations

:

: This podcast was sponsored by Pfizer. No funding was provided for the authoring of this review. The authors received no honoraria related to the development of this publication. Medical writing support was provided by Anne Marie McGonigal, PhD, CMPP, of Engage Scientific Solutions and funded by Pfizer.

: Jeffrey Lipton has been a consultant for Bristol Myers Squibb, Novartis, Pfizer, and Takeda (currently only with Pfizer and Takeda); has received research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda and honoraria from Bristol Myers Squibb, Novartis, Incyte, Pfizer, and Takeda. Jorge E Cortes has served as a consultant for Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda and has received research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Tovagene.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

: Jeffrey H Lipton and Jorge E Cortes made substantial contributions to the article concept/design, critically reviewed and revised the manuscript drafts, and provided final approval of the article and enhanced content as submitted.